Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience

被引：7

作者：

Caldarola, Giacomo ^{[1
,2
]}

Zangrilli, Arianna ^{[3
]}

Palmisano, Gerardo ^{[1
,2
]}

Bavetta, Mauro ^{[4
]}

Moretta, Gaia ^{[5
]}

Pagnanelli, Gianluca ^{[6
]}

Panasiti, Vincenzo ^{[6
]}

Bianchi, Luca ^{[3
]}

De Simone, Clara ^{[1
,2
]}

Peris, Ketty ^{[1
,2
]}

机构：

[1] Univ Cattolica Sacro Cuore, Ist Dermatol, Lgo F Vito 1, I-00135 Rome, Italy

[2] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[3] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy

[4] Osped San Sebastiano, UOC Dermatol, Frascati, RM, Italy

[5] Ist Dermopat Immacolata IRCCS, Rome, Italy

[6] Campus Biomed Univ, Plast & Reconstruct Surg Unit, Rome, Italy

来源：

DRUGS IN CONTEXT | 2023年 / 12卷

关键词：

efficacy; IL-23; psoriasis; real-life; risankizum-; ab; safety; EFFICACY;

D O I：

10.7573/dic.2023-1-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar involvement, over a 52- week treatment period. Methods: We performed a retrospective analysis in a cohort of patients with PP, with or without involvement of other skin sites. Palmoplantar Psoriasis Area and Severity Index (ppPASI) was assessed at baseline and after 4, 16, 28 and 52 weeks, to evaluate the PP severity. Results: Sixteen patients were enrolled. The rates of ppPASI90 responses constantly increased during the period of observation and were 18.7%, 62.2%, 75.0% and 81.2% at weeks 4, 16, 28 and 52, respectively. Only two patients suspended treatment because of ineffectiveness at week 16. Conclusion: Our data from a series of 16 patients reveal that risankizumab could represent an effective and safe therapeutic choice in patients with PP.

引用

页数：5

共 15 条

[1] Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report [J].

Al Muqrin, Abdullah Muqrin ;

Alghamdi, Abdulaziz A. ;

AlShaalan, Ziad M. .

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2022, 15 :2129-2132

[2] Palmoplantar Psoriasis Successfully Treated With Risankizumab [J].

Alajlan, Abdulmajeed M. ;

Qadoumi, Tala A. .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)

[3] Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study [J].

Bissonnette, R. ;

Poulin, Y. ;

Guenther, L. ;

Lynde, C. W. ;

Bolduc, C. ;

Nigen, S. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (12) :1402-1408

[4] Risankizumab: A Review in Moderate to Severe Plaque Psoriasis [J].

Blair, Hannah A. .

DRUGS, 2020, 80 (12) :1235-1245

[5] Severe and resistant palmar psoriasis successfully treated with risankizumab [J].

Calabrese, Laura ;

Caldarola, Giacomo ;

Peris, Ketty ;

Simone, Clara De .

ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2022, 157 (01) :118-119

[6] Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study [J].

Caldarola, Giacomo ;

Zangrilli, Arianna ;

Bernardini, Nicoletta ;

Bavetta, Mauro ;

De Simone, Clara ;

Graceffa, Dario ;

Bonifati, Claudio ;

Faleri, Sara ;

Giordano, Domenico ;

Mariani, Marco ;

Micheli, Adriana ;

Moretta, Gaia ;

Pagnanelli, Gianluca ;

Panasiti, Vincenzo ;

Provini, Alessia ;

Richetta, Antonio ;

Peris, Ketty ;

Bianchi, Luca .

DERMATOLOGIC THERAPY, 2022, 35 (06)

[7]

Elewski BE, 2022, 31 C EUR AC DERM VEN

[8] Palmoplantar psoriasis [J].

Engin, Burhan ;

Askin, Ozge ;

Tuzun, Yalcin .

CLINICS IN DERMATOLOGY, 2017, 35 (01) :19-27

[9] Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial [J].

Gottlieb, Alice ;

Sullivan, John ;

van Doorn, Martijn ;

Kubanov, Alexey ;

You, Ruquan ;

Parneix, Anne ;

Hugot, Sophie ;

Milutinovic, Marina .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (01) :70-80

[10] Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study [J].

Megna, Matteo ;

Tommasino, Nello ;

Potestio, Luca ;

Battista, Teresa ;

Ruggiero, Angelo ;

Noto, Matteo ;

Fabbrocini, Gabriella ;

Genco, Lucia .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (06) :2813-2820

← 1 2 →